NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced a new agreement to bring Flatiron Assist™ advanced cancer care insights to oncology care clinicians at Penn Medicine’s Abramson Cancer Center (ACC).
The collaboration between Flatiron Health and Penn Medicine will focus on further enabling clinicians at ACC to determine and promote site-preferred pathways and open clinical trials at the point of care alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Access to evidence-based treatment recommendations will promote high levels of guideline-concordant care, while improving health equity and patient experiences and reducing unnecessary spending. The two organizations will also work together to optimize the usability and functionality of Flatiron Assist™.
Flatiron Assist™ is an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways and clinical research at the point of care. The EHR-integrated platform incorporates NCCN Guidelines for the 26 most common cancers as well as site-preferred treatment pathways and relevant clinical trial opportunities for patients at the point of care.
Flatiron Assist™’s high provider adoption has driven positive outcomes for cancer centers, yielding results such as an 88% concordance with NCCN guidelines¹ and a 44% reduction in unique regimens ordered across cancer centers.²
“At Flatiron, we are committed to elevating clinical care and unlocking the power of patient data, so every person’s experience can inform and improve outcomes for future patients. Partnering with Penn Medicine’s Abramson Cancer Center, a market-leading cancer care provider and a pioneer of digital innovation in healthcare, enables us to use data for good and reimagine the infrastructure of cancer care,” said Julia Morton SVP and GM of Flatiron HC. “We are looking forward to working together to accelerate the delivery of more standardized, efficient, and effective cancer care across the entire health system.”
The goals of this collaboration include launching Flatiron Assist™ with NCCN preferred guidelines across all diseases while working to develop ACC-preferred pathways across specialized diseases. Flatiron Assist drives over 84% selection of site-preferred regimens across users at cancer centers.³
The project will also aim to leverage Flatiron Assist™ technology to increase awareness of clinical trial opportunities and drive user adoption and satisfaction. On average, Flatiron Assist™ users typically see 80% clinician adoption.⁴ The two organizations will track usage patterns and tie the results to financial impacts for the health system.
“We are excited to support our oncology clinicians in providing evidence-based treatment while improving clinical and administrative efficiencies,” said Lawrence N. Shulman, MD, a professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania and the associate director of special projects at ACC. “As cancer care options increase in complexity, this tool will help provide high-quality, guideline-concordant care, maximizing benefits for our patients.”
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth
References
- Jonas M. Congelli, Rebecca Maniago, Stephanie Jou, Janet Donegan and Ivy Altomare. Official Journal of the National Comprehensive Cancer Network. Volume 20: Issue 3.5, March 31, 2022. https://jnccn.org/view/journals/jnccn/20/3.5/article-pBPI22-015.xml#:~:text=https%3A//doi.org/10.6004/jnccn.2021.7262
- Jonas M. Congelli, Heather Lewin, Gregory Calip, Marcello Ricottone, Shawn Huda, Taylor Dias-Foundas and Rebecca Maniago. Official Journal of the National Comprehensive Cancer Network. Volume 21: Issue 3.5, March 31, 2023. https://jnccn.org/view/journals/jnccn/21/3.5/article-pQIM23-132.xml
- Rebecca Maniago, Marcello Ricottone, Gregory Calip, Taylor Dias-Foundas, James Hamrick. Journal of Clinical Pathways. 2023;9(3):22-24. doi:10.25270/jcp.2023.05.02 https://www.hmpgloballearningnetwork.com/site/jcp/research-reports/can-we-fill-gaps-authoring-custom-oncology-pathways-vs-surfacing-nccn
- Rebecca Maniago, Sylvia S. Richey, Sarah DeVincenzo, Stephanie Jou, Robin Linzmayer, Janet Donegan, Gregory Sampang Calip, Ivy Altomare. Journal of Clinical Oncology. Volume 39: Issue 28_suppl, 274-274 https://ascopubs.org/doi/abs/10.1200/JCO.2020.39.28_suppl.274?af=R
